Report from the 59th American Society of Hematology Annual Meeting — Benign Hematology

Editors from NEJM Journal Watch Oncology and Hematology covered the American Society of Hematology (ASH) meeting, held December 9 to 12, 2017, in Atlanta, GA. Here, Dr. David Green describes the latest findings in benign hematology. The original abstracts can be found at the ASH website.

Direct Oral Anticoagulants vs. Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis

Treatment for venous thromboembolism (VTE) in cancer patients was addressed by two groups of investigators.

Young and colleagues conducted a prospective, randomized, open-label pilot study (Select-d; abstract 625) to compare 6 months of treatment with the direct oral anticoagulant rivaroxaban (15 mg twice daily for 3 weeks then 20 mg daily) versus the low-molecular-wei…